The group is engaged in the development of innovative therapeutic solutions using different nanocarriers and nanoformulations. This strategy provides an outstanding platform to improve pharmacokinetics and modulate ADMET properties, mainly water solubility, membrane permeability and metabolic stability. The project is sustained by strong collaborations with national and international organisations and by the European Technology Platform on Nanomedicine.
Fernandes C, Martins C, Fonseca A, Nunes R, Matos M J, Silva R, Garrido J, Sarmento B, Remião F, Espinar-Otero F, Uriarte E, Borges F. PEGylated PLGA Nanoparticles as a Smart Carrier to Increase the Cellular Uptake of a Coumarin-Based Monoamine Oxidase B Inhibitor, ACS Appl. Mater., 2018, 10:39557–39569.
Fernandes C, Benfeito S, Amorim R, Teixeira J, Oliveira P J, Remião F, Borges F. Desrisking the Cytotoxicity of a Mitochondriotropic Antioxidant Based on Caffeic Acid by a PEGylated Strategy, Bioconjug. Chem., 2018, 29:2723–2733.
Fernandes C, Pinto M, Martins C, Gomes M J, Sarmento B, Oliveira P J, Remião F, Borges F. Development of a PEGylated-based Platform for Efficient Delivery of Dietary Antioxidants Across the Blood–Brain Barrier, Bioconjug. Chem., 2018, 29:1677-1689.